ChiNing decoction

Phase 3Small molecule

TTianjin Medical University Cancer Institute and Hospital

ChiNing decoction is one of 16 small molecule programs targeting Stomatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

StomatitisActive, not recruiting

StomatitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Stomatitis

#DrugCompanyPhaseTrials

DATROWAY

Daiichi Sankyo

Approved

1 2

Mycostatin

GGood Molecules, LLC

Approved

1 3

Xylocaine

MMEDRx USA, Inc.

Approved

—4

Neo-Synephrine

EExela Pharma Sciences, LLC.

Afinitor

1 6

Decadron

AAspen Global Incorporated

Phase 3

2 7

Kepivance

SSwedish Orphan Biovitrum

Thalomid

1 9

Dexamethasone Mouthwash

WWoman's

Approved

1 10

Valtrex

GGlaxo Dba Glaxosmithkline

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Stomatitis1 trial

Clinical Trial on the Efficacy and Safety of Chining Decoction in the Treatment of Radiation Stomatitis

Completed·TTianjin Medical University Cancer Institute and Hospital·Phase 3·NCT02303197·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ChiNing decoction. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ChiNing decoction compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ChiNing decoction. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tianjin Medical University Cancer Institute and Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTianjin Medical University Cancer Institute and Hospital

ChiNing decoction

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Stomatitis1 trial

References

Drug Info

Quick Facts

Related News